Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.37 USD | -3.32% | +7.68% | -11.88% |
May. 30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
May. 16 | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.88% | 186M | |
+45.75% | 56.65B | |
-6.52% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+11.89% | 26.75B | |
-21.60% | 19.03B | |
+0.51% | 12.28B | |
+23.68% | 12.26B | |
+27.48% | 12.04B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- Abeona Therapeutics Seeks FDA Priority Review for Potential Treatment of Recessive Dystrophic Epidermolysis Bullosa